Cue Biopharma Reports $7.9M Collaboration Revenue and $153.1M Net Loss for Q2 2026

Cue Biopharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated collaboration revenue of $7.9 million for the quarter, a substantial increase from $3.0 million in the same period last year. For the first half of 2026, total collaboration revenue reached $13.6 million, compared to $3.4 million in the first half of 2025. Despite this revenue growth, Cue Biopharma incurred a net loss of $153.1 million for the quarter, a sharp increase from a loss of $8.5 million in the prior year, primarily due to increased operating expenses.

Operating expenses surged to $95.6 million for the quarter, up from $11.6 million a year earlier. This increase was largely driven by a $40.6 million rise in general and administrative expenses, which included significant stock-based compensation and payroll tax expenses related to restricted stock units granted in the second quarter. Research and development expenses also rose to $49.0 million, reflecting costs associated with a new license agreement with Ascendant Health Sciences, which included a $15 million upfront payment and additional non-cash expenses.

In terms of strategic developments, Cue Biopharma entered into a License Agreement with Ascendant Health on April 30, 2026, granting it exclusive rights to develop and commercialize the anti-IgE monoclonal antibody CUE-221. The agreement includes potential milestone payments totaling up to $676.5 million, alongside tiered royalty payments on future net sales. The company also reported a significant increase in its employee headcount, reflecting its ongoing expansion efforts in research and development.

As of June 30, 2026, Cue Biopharma had cash and cash equivalents of $17.4 million, down from $27.1 million at the end of 2025. The company anticipates that its current cash position, along with net proceeds from a recent private placement of approximately $49.8 million in July 2026, will be sufficient to meet its operating needs for at least the next twelve months. However, Cue Biopharma acknowledged the necessity of raising additional capital to support its ongoing research and development activities, particularly for its lead drug candidates, CUE-221 and CUE-401, as it continues to navigate the complexities of clinical trials and regulatory approvals.